The World of Dementia Beyond 2020
The World of Dementia Beyond 2020
复制标题
DOI：
10.1111/j.1532-5415.2011.03365.x
复制
发表时间：
2011-05-01
影响因子：
6.3
通讯作者：
De Strooper, Bart
中科院分区：
文献类型：
--
作者：
Brodaty, Henry;Breteler, Monique M. B.;De Strooper, Bart
与未来40年痴呆症患病率将增加两倍的可怕预测相抗衡的是诊断生物标志物、神经影像学、阿尔茨海默病（AD）的分子生物学、风险和保护因素的流行病学以及药物治疗（主要针对淀粉样蛋白途径、tau蛋白和免疫治疗）的重大发展，这些可能有可能改变AD的进展。药物组合和症状前治疗也正在研究中。以前的痴呆症改善药物试验没有显示出益处，即使目前的III期试验证明是成功的，这些药物也不会根除其他痴呆症，可能（如果不是治愈性的）增加痴呆症的持续时间和患病率，并且不太可能在2020年之前上市。与此同时，即使将痴呆症的发病时间推迟两年，也会产生重大的经济和社会影响。本文概述了基础和临床研究的当前成就和潜力，这些研究可能会影响痴呆症患病率和护理在不久的将来的发展。J Am Geriatr Soc 59：923-927，2011.
Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments-mainly targeting the amyloid pathway, tau protein, and immunotherapy-that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia-modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could ( if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future. J Am Geriatr Soc 59:923-927, 2011.